SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Bonanni Laura)
 

Search: WFRF:(Bonanni Laura) > Cerebrospinal fluid...

Cerebrospinal fluid Alzheimer's disease biomarkers across the spectrum of lewy body diseases : Results from a large multicenter cohort

Van Steenoven, Inger (author)
Amsterdam UMC - Vrije Universiteit Amsterdam
Aarsland, Dag (author)
Karolinska Institutet
Weintraub, Daniel (author)
University of Pennsylvania
show more...
Londos, Elisabet (author)
Lund University,Lunds universitet,Klinisk minnesforskning,Forskargrupper vid Lunds universitet,Clinical Memory Research,Lund University Research Groups
Blanc, Frederic (author)
University Hospital Of Strasbourg
Van Der Flier, Wiesje M. (author)
Amsterdam UMC - Vrije Universiteit Amsterdam
Teunissen, Charlotte E. (author)
Amsterdam UMC - Vrije Universiteit Amsterdam
Mollenhauer, Brit (author)
University of Göttingen
Fladby, Tormod (author)
Akershus University Hospital
Kramberger, Milica G. (author)
University Medical Centre Ljubljana
Bonanni, Laura (author)
University G.d'Annunzio of Chieti-Pescara
Lemstra, Afina W. (author)
Amsterdam UMC - Vrije Universiteit Amsterdam
Blanc, 'E (author)
show less...
 (creator_code:org_t)
2016
2016
English 9 s.
In: Journal of Alzheimer's Disease. - 1387-2877 .- 1875-8908. ; 54:1, s. 287-295
  • Journal article (peer-reviewed)
Abstract Subject headings
Close  
  • Background: Concomitant Alzheimer's disease (AD) pathology is observed in Lewy body diseases (LBD), but the clinical impact is unknown. Only a few biomarker studies in LBD exist and have included small cohorts from single centers. Objective: We aimed to evaluate the prevalence of abnormal cerebrospinal fluid (CSF) AD biomarkers across the spectrum of LBD in a large multicenter cohort and to assess whether an AD biomarker profile was associated with demographic and clinical differences in dementia with Lewy bodies (DLB). Methods:We included 375 DLB patients, 164 Parkinson's disease (PD) patients without dementia, and 55 PD patients with dementia (PDD) from 10 centers. CSF amyloid-beta42 (Aβ42), total tau (t-tau), and phosphorylated tau (p-tau) values were dichotomized as abnormal or normal according to locally available cut-off values. A CSF AD profile was defined as abnormal Aβ42 combined with abnormal t-tau and/or p-tau. Results: A substantial proportion of DLB patients had abnormal values for CSF Aβ42, t-tau, and p-tau, while abnormal values were uncommon in PD without dementia. Patients with PDD had values in between. A CSF AD profile was observed in 25% of DLB patients, compared with only 9% of PDD and 3% of PD without dementia.Within DLB, patients with a CSF AD profile were older, more often female, performed worse on the Mini-Mental State Examination, and had shorter disease duration compared with patients with normal CSF. Conclusion: A CSF AD profile is more common in DLB compared with PDD and PD, and is associated with more severe cognitive impairment in DLB.

Subject headings

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Neurologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Neurology (hsv//eng)

Keyword

Amyloid beta-protein (1-42)
Biomarkers
Cerebrospinal fluid
Dementia with Lewy bodies
Lewy body disease
Tau protein

Publication and Content Type

art (subject category)
ref (subject category)

Find in a library

To the university's database

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view